acetyl-11-ketoboswellic-acid and beta-amyrin

acetyl-11-ketoboswellic-acid has been researched along with beta-amyrin* in 2 studies

Other Studies

2 other study(ies) available for acetyl-11-ketoboswellic-acid and beta-amyrin

ArticleYear
Acetyl-11-keto-beta-boswellic acid induces apoptosis in HL-60 and CCRF-CEM cells and inhibits topoisomerase I.
    The Journal of pharmacology and experimental therapeutics, 1999, Volume: 288, Issue:2

    Antiproliferative action of different pentacyclic triterpenes has repeatedly been reported, and some lipoxygenase inhibitors have been shown to induce cell death in various cell systems. Acetyl-11-keto-beta-boswellic acid (AKBA) is a pentacyclic triterpene that inhibits 5-lipoxygenase in a selective, enzymedirected, nonredox, and noncompetitive manner. To investigate a possible effect of AKBA on leukemic cell growth, proliferation of HL-60 and CCRF-CEM cells was assayed in the presence of AKBA and a structural analog without effect on 5-lipoxygenase, amyrin. Cell counts and [3H]thymidine incorporation were significantly reduced in a dose-dependent manner in the presence of AKBA (IC50 = 30 microM) but not amyrin. An additive effect of AKBA with the crosslinking of the CD95 receptor was also observed. Flow cytometric analysis of propidium iodide-stained cells indicated that the cells underwent apoptosis. This was confirmed by flow cytometric detection of sub-G1 peaks in AKBA-treated cells and by DNA laddering. However, because HL-60 and CCRF-CEM do not express 5-lipoxygenase mRNA constitutively, a mechanism distinct from inhibition of 5-lipoxygenase must account for the effect of AKBA. In a DNA relaxation assay with phiX174RF DNA, AKBA inhibited topoisomerase I from calf thymus at concentrations of >/=10 microM. A semiquantitative cDNA polymerase chain reaction approach was used to estimate the relative level of expression of topoisomerases in both cell lines. The data suggest that induction of apoptosis in HL-60 and CCRF-CEM by AKBA may be due to inhibition of topoisomerase I in these cells.

    Topics: Animals; Antigens, Neoplasm; Antineoplastic Agents; Apoptosis; Arachidonate 5-Lipoxygenase; Cell Division; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; DNA-Binding Proteins; DNA, Neoplasm; HL-60 Cells; Humans; Isoenzymes; Leukemia, T-Cell; Lipoxygenase Inhibitors; Oleanolic Acid; Rats; RNA, Messenger; Topoisomerase I Inhibitors; Triterpenes; Tumor Cells, Cultured

1999
Characterization of an acetyl-11-keto-beta-boswellic acid and arachidonate-binding regulatory site of 5-lipoxygenase using photoaffinity labeling.
    European journal of biochemistry, 1998, Sep-01, Volume: 256, Issue:2

    AKBA (acetyl-11-keto-beta-boswellic acid), a natural pentacyclic triterpene, is an orally active leukotriene-synthesis inhibitor, which acts by a 5-lipoxygenase-directed, non-redox, non-competitive mechanism. It is the only leukotriene-synthesis inhibitor so far identified that inhibits 5-lipoxygenase activity as an allosteric regulator and not by a reducing or competitive mechanism. To characterize AKBA's effector site we prepared azido125I-KBA (4-azido-5-125iodo-salicyloyl-beta-alanyl-11-keto-beta-bo swellic acid) as a photoaffinity analogue, which inhibited 5-lipoxygenase activity as efficiently as the lead compound and specifically labeled human 5-lipoxygenase protein. The labeling of 5-lipoxygenase by azido-125I-KBA strictly depended on the presence of calcium ([Ca2+]free > 500 nM) and was abolished by heat denaturation or by prior incubation with a series of pentacyclic triterpenes (e.g., amyrin, beta-boswellic acid, AKBA and 18a-glycyrrhetinic acid). In contrast, 18-beta-glycyrrhetinic acid and competitive 5-lipoxygenase inhibitors (e.g., ZM-230,487 and L-739,010) did not affect labeling. Arachidonic acid, in enzyme-activity-inhibiting concentrations, reduced photoincorporation (IC50 about 10 microM), whereas a variety of other long-chain fatty acids and their derivatives (e.g., arachidinic acid, arachidonic acid methyl ester, lipoxins A4 and B4) had no effect. The inhibitory arachidonate action on labeling was not affected by blocking the substrate-binding site by micromolar amounts of the competitive inhibitor L-739,010. Therefore, we suggest that AKBA binds in presence of calcium to a site which is distinct from the substrate binding site of 5-lipoxygenase. The AKBA-binding site is likely to be identical with a regulatory, second arachidonate binding site of the enzyme.

    Topics: Affinity Labels; Arachidonate 5-Lipoxygenase; Arachidonic Acid; Azo Compounds; Binding Sites; Binding, Competitive; Bridged Bicyclo Compounds; Calcium; Humans; Leukocytes; Lipoxygenase Inhibitors; Molecular Structure; Oleanolic Acid; Quinolines; Triterpenes

1998